East Oregonian

Aptitude Receives FDA Authorization for Metrix® COVID/Flu Multiplex Molecular Test for Point-of-Care and Over-the-Counter Use

The FDA-authorized Metrix COVID/Flu molecular test detects and differentiates COVID, Flu A, and B in 20 minutes. It may be used in home and CLIA-waived settings. SANTA BARBARA, Calif., Feb. 24, 2025 ...
Nasdaq

LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay

LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully validated by the UK Health Security Agency (UKHSA) under the ...
Business Wire

Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care Use

SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced ...
Seeking Alpha

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA

SALT LAKE CITY, Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular ...